Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer

Cancer Research

Volumn 59, Issue 20, 1999, Pages 5160-5168

  Simons, Jonathan W ^a,e   Mikhak, Bahar ^a   Chang, Ju Fay ^d   DeMarzo, Angelo M ^a   Carducci, Michael A ^a   Lim, Michael ^a   Weber, Christine E ^a   Baccala, Angelo A ^a   Goemann, Marti A ^a   Clift, Shirley M ^d   Ando, Dale G ^d   Levitsky, Hyam I ^a   Cohen, Lawrence K ^c   Sanda, Martin G ^b   Mulligan, Richard C ^c   Partin, Alan W ^a   Carter, H Ballentine ^a   Piantadosi, Steven ^a   Marshall, Fray F ^a   Nelson, William G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d CELL GENESYS INC   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CD45 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROSTATE SPECIFIC ANTIGEN; TUMOR VACCINE;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; DENDRITIC CELL; EDEMA; ERYTHEMA; GENE THERAPY; HELPER CELL; HUMAN; HUMAN CELL; INTRADERMAL DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PRURITUS; VASCULITIS;

ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CANCER VACCINES; GENE TRANSFER TECHNIQUES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPERSENSITIVITY, DELAYED; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; VACCINATION; VACCINES, SYNTHETIC;

EID: 0032741439     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Tjoa, B. A., Erickson, S. J., Bowes, V. A., Ragde, H., Kenny, G. M., Cobb, O. E., Ireton, R. C., Troychak, M. J., Boynton, A. L., and Murphy, G. P. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate, 32: 272-278, 1997.
2. Tjoa, B. A., Simmons, S. J., Bowes, V. A., Ragde, H., Rogers, M., Elgamal, A., Kenny, G. M., Cobb, O. E., Ireton, R. C., Troychak, M. J., Salgaller, M. L., Boynton, A. L., and Murphy, G. P. Evaluation of Phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate, 36: 39-44, 1998.
3. Salgaller, M. L., Lodge, P. A., McLean, J. G., Tjoa, B. A., Loftus, D. J., Ragde, H., Kenny, G. M., Rogers, M., Boynton, A. L., and Murphy, G. P. Report of immune monitoring of prostate cancer patients undergoing T- cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate, 35: 144-151, 1998.
4. Zhang, S., Zhang, H. S., Reuter, V. E., Slovin, S. F., Scher, H. I., and Livingston, P. O. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin. Cancer Res., 4: 295-302, 1998.
5. Slovin, S. F., Livingston, P. O., Rosen, N., Sepp-Lorenzino, L., Kelly, W. K., Mendelsohn, J., and Scher, H. I. Targeted therapy for prostate cancer: the Memorial Sloan-Ketterirg Cancer Center approach. Semin Oncol., 23: 41-48, 1996.
6. Peshwa, M. V., Shi, J. D., Ruegg, C., Laus, R., and van Schooten, W. C. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate, 36: 129-138, 1998.
7. Hodge, J. W., Schlom, J., Donohue, S. J., Tomaszewski, J. E., Wheeler, C. W., Levine, B. S., Gritz, L., Panicali, D., and Kantor, J. A. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int. J. Cancer, 63: 231-237, 1995.
8. Xue, B. H., Zhang, Y., Sosman, J. A., and Peace, D. J. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate, 30: 73-78, 1997.
9. Correale, P., Walmsley, K., Nieroda, C., Zaremba, S., Zhu, M., Schlom, J., and Tsang, K. Y. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst., 89: 293-300, 1997.
10. Correale, P., Walmsley, K., Zaremba, S., Zhu, M., Schlom, J., and Tsang, K. Y. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J. Immunol., 161: 3186-3194, 1998.
11. Simons, J. W., and Mikhak, B. Ex vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology. Semin Oncol., 25: 661-676, 1998.
12. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
13. Thompson, R. C., Pardoll, D. M., Jaffee, E. M., Ewend, M. G., Thomas, M. C., Tyler, B. M., and Brem, H. Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J. Immunother. Emphasis Tumor Immunol., 19: 405-413, 1996.
14. Jaffee, E. M., Thomas, M. C., Huang, A. Y., Hauda, K. M., Levitsky, H. I., and Pardoll, D. M. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J. Immunother. Emphasis Tumor Immunol., 19: 176-183, 1996.
15. Abe, J., Wakimoto, H., Yoshida, Y., Aoyagi, M., Hirakawa, K., and Hamada, H. Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction. J. Cancer Res. Clin. Oncol., 121: 587-592, 1995.
16. Schmidt, W., Schweighoffer, T., Herbst, E., Maass, G., Berger, M., Schilcher, F., Schaffner, G., and Bimstiel, M. L. Cancer vaccines: the interleukin 2 dosage effect. Proc. Natl. Acad. Sci. USA, 92: 4711-4714, 1995.
17. Wakimoto, H., Abe, J., Tsunoda, R., Aoyagi, M., Hirakawa, K., and Hamada, H. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res., 56: 1828-1833, 1996.
18. Hsieh, C. L., Pang, V. F., Chen, D. S., and Hwang, L. H. Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens. Hum. Gene Ther., 8: 1843-1854, 1997.
19. Shrayer, D. P., Bogaars, H., Wolf, S. F., Hearing, V. J., and Wanebo, H. J. A new mouse model of experimental melanoma for vaccine and lymphokine therapy. Int. J. Oncol., 13: 361-374, 1998.
20. Hurwitz, A. A., Yu, T. F., Leach, D. R., and Allison, J. P. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA, 95: 10067-10071, 1998.
21. Sampson, J. H., Archer, G. E., Ashley, D. M., Fuchs, H. E., Hale, L. P., Dranoff, G., and Bigner, D. D. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc. Natl. Acad. Sci. USA, 93: 10399-10404, 1996.
22. Herrlinger, U., Kramm, C. M., Johnston, K. M., Louis, D. N., Finkelstein, D., Reznikoff, G., Dranoff, G., Breakefield, X. O., and Yu, J. S. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther., 4: 345-352, 1997.
23. Dunussi-Joannopoulos, K., Dranoff, G., Weinstein, H. J., Ferrara, J. L., Bierer, B. E., and Croop, J. M. Gene immunotherapy in murine acute myeloid leukemia: granulocyte- macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood, 91: 222-230, 1998.
24. Sanda, M. G., Ayyagari, S. R., Jaffee, E. M., Epstein, J. I., Clift, S. L., Cohen, L. K., Dranoff, G., Pardoll, D. M., Mulligan, R. C., and Simons, J. W. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol., 151: 622-628, 1994.
25. Carducci, M. A., Ayyagari, S. R., Sanda, M. G., and Simons, J. W. Gene therapy for human prostate cancer. Cancer (Phila.), 75: 2013-2020, 1995.
26. Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J. C., Hodi, F. S., Liebster, L., Lam, P., Mentzer, S., Singer, S., Tanabe, K. K., Cosimi, A. B., Duda, R., Sober, A., Bhan, A., Daley, J., Neuberg, D., Parry, G., Rokovich, J., Richards, L., Drayer, J., Berns, A., Clift, S., Dranoff, G., et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA, 95: 13141-13146, 1998.
27. Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. I., Nelson, W. G., Carducci, M. A., Lazenby, A. J., Cohen, L. K., Finn, C. C., Clift, S. M., Hauda, K. M., Beck, L. A., Leiferman, K. M., Owens, A. H., Jr., Piantadosi, S., Dranoff, G., Mulligan, R. C., Pardoll, D. M., and Marshall, F. F. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex. vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res., 57: 1537-1546, 1997.
28. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., and Levitsky, H. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med., 188: 2357-2368, 1998.
29. Chan, A. D., and Morton, D. L. Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol., 25: 611-622, 1998.
30. Berns, A. J., Clift, S., Cohen, L. K., Donehower, R. C., Dranoff, G., Hauda, K. M., Jaffee, E. M., Lazenby, A. J., Levitsky, H. I., Marshall, F. F., Mulligan, R. C., Nelson, W. G., Owens, A. H., Pardoll, D. M., Parry, G., Partin, A. H., Piantadosi, A., Simons, J. W., and Zabora, J. R. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum. Gene Ther., 6: 347-368, 1995.
31. Woodcock-Mitchell, J., Eichner, R., Nelson, W. G., and Sun, T. T. Immunolocalization of keratin polypeptides in human epidermis using monoclonal antibodies. J. Cell Biol., 95: 580-588, 1982.
32. Pulford, K. A., Rigney, E. M., Micklem, K. J., Jones, M., Stross, W. P., Gatter, K. C., and Mason, D. Y. KP1: a new monoclonal antibody that detects a monocyte/ macrophage associated antigen in routinely processed tissue sections. J. Clin. Pathol., 42: 414-421, 1989.
33. Krenacs, L., Tiszalvicz, L., Krenacs, T., and Boumsell, L. Immunohistochemical detection of CD1A antigen in formalin-fixed and paraffin-embedded tissue sections with monoclonal antibody 010. J. Pathol., 171: 99-104, 1993.
34. Husmann, M., Pietsch, T., Fleischer, B., Weisgerber, C., and Bitter-Suermann, D. Embryonic neural cell adhesion molecules on human natural killer cells. Eur. J. Immunol., 19: 1761-1763, 1989.
35. Moolenaar, C. E., Muller, E. J., Schol, D. J., Figdor, C. G., Bock, E., Bitter-Suermann, D., and Michalides, R. J. Expression of neural cell adhesion molecule-related sialo-glycoprotein in small cell lung cancer and neuroblastoma cell lines H69 and CHP-212. Cancer Res., 50: 1102-1106, 1990.
36. Warnke, R. A., Gatter, K. C., Falini, B., Hildreth, P., Woolston, R. E., Pulford, K., Cordell, J. L., Cohen, B., De Wolf-Peelers, C., and Mason, D. Y. Diagnosis of human lymphoma with monoclonal antileukocyte antibodies. N. Engl. J. Med., 309: 1275-1281, 1983.
37. Campana, D., Thompson, J. S., Amlot, P., Brown, S., and Janossy, G. The cytoplasmic expression of CD3 antigens in normal and malignant cells of the T lymphoid lineage. J. Immunol., 138: 648-655, 1987.
38. Mason, D. Y., Cordell, J. L., Gaulard, P., Tse, A. G., and Brown, M. H. Immunohistological detection of human cytotoxic/suppressor T cells using antibodies to a CD8 peptide sequence. J. Clin. Pathol., 45: 1084-1088, 1992.
39. Clement, L. T. Isoforms of the CD45 common leukocyte antigen family: markers for human T-cell differentiation. J. Clin. Immunol., 12: 1-10, 1992.
40. Ishii, Y., Takami, T., Yuasa, H., Takei, T., and Kikuchi, K. Two distinct antigen systems in human B lymphocytes: identification of cell surface and intracellular antigens using monoclonal antibodies. Clin. Exp. Immunol., 58: 183-192, 1984.
41. Key, G., Becker, M. H., Baron, B., Duchrow, M., Schluter, C., Flad, H. D., and Gerdes, J. New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab. Invest., 68: 629-636, 1993.
42. Moqbel, R., Barkans, J., Bradley, B. L., Durham, S. R., and Kay, A. B. Application of monoclonal antibodies against major basic protein (BMK-13) and eosinophil cationic protein (EG1 and EG2) for quantifying eosinophils in bronchial biopsies from atopic asthma. Clin. Exp. Allergy, 22: 265-273, 1992.
43. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A., and Murphy, G. P. LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.
44. Kaighn, M. E., Narayan, K. S., Ohnuki, Y., Lechner, J. F., and Jones, L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol., 17: 16-23, 1979.
45. Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., and Paulson, D. F. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer, 21: 274-281, 1978.
46. Shapiro, D. L., Nardone, L. L., Rooney, S. A., Motoyama, E. K., and Munoz, J. L. Phospholipid biosynthesis and secretion by a cell line (A549) which resembles type II aleveolar epithelial cells. Biochim. Biophys. Acta, 530: 197-207, 1978.
47. Tom, B. H., Rutzky, L. P., Jakstys, M. M., Oyasu, R., Kaye, C. I., and Kahan, B. D. Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro, 12: 180-191, 1976.
48. Richardson, G. S., Dickersin, G. R., Atkins, L., MacLaughlin, D. T., Raam, S., Merk, L. P., and Bradley, F. M. KLE: a cell line with defective estrogen receptor derived from undifferentiated endometrial cancer. Gynecol. Oncol., 17: 213-230, 1984.
49. Gillis, S., and Watson, J. Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line. J. Exp. Med., 152: 1709-1719, 1980.
50. Cailleau, R., Young, R., Olive, M., and Reeves, W. J., Jr. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst., 53: 661-674, 1974.
51. Cailleau, R., Olive, M., and Cruciger, Q. V. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro, 14: 911-915, 1978.
52. Corman, J. M., Sercarz, E. E., and Nanda, N. K. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin. Exp. Immunol., 114: 166-172, 1998.
53. Sokal, J. E. Editorial. Measurement of delayed skin-test responses. N. Engl. J. Med., 293: 501-502, 1975.
54. McCune, C. S., O'Donnell, R. W., Marquis, D. M., and Sahasrabudhe, D. M. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother., 32: 62-66, 1990.
55. Oren, M. E., and Herberman, R. B. Delayed cutaneous hypersensitivity reactions to membrane extracts of human tumour cells. Clin. Exp. Immunol., 9: 45-56, 1971.
56. Hoover, H. C., Jr., Surdyke, M., Dangel, R. B., Peters, L. C., and Hanna, M. G., Jr. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guerin vaccine. Cancer Res., 44: 1671-1676, 1984.
57. Berd, D., Maguire, H. C., Jr., and Mastrangelo, M. J. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res., 46: 2572-2577, 1986.
58. Berd, D., Maguire, H. C., Jr., McCue, P., and Mastrangelo, M. J. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J. Clin. Oncol., 8: 1858-1867, 1990.
59. Healy, C. G., Simons, J. W., Carducci, M. A., DeWeese, T. L., Bartkowski, M., Tong, K. P., and Bolton, W. E. Impaired expression and function of signal-transducing ζ chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry, 32: 109-119, 1998.
60. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.
61. Huang, A. Y., Bruce, A. T., Pardoll, D. M., and Levitsky, H. I. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity, 4: 349-355, 1996.
62. Natali, P. G., Nicotra, M. R., Bigotti, A., Venturo, I., Marcenaro, L., Giacomini, P., and Russo, C. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc. Natl. Acad. Sci. USA, 86: 6719-6723, 1989.
63. Blades, R. A., Keating, P. J., McWilliam, L. J., George, N. J., and Stern, P. L. Loss of HLA class 1 expression in prostate cancer: implications for immunotherapy. Urology, 46: 681-686; Discussion, 686-687, 1995.
64. Sanda, M. G., Restifo, N. P., Walsh, J. C., Kawakami, Y., Nelson, W. G., Pardoll, D. M., and Simons, J. W. Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst., 87: 280-285, 1995.
65. Bander, N. H., Yao, D., Liu, H., Chen, Y. T., Steiner, M., Zuccaro, W., and Moy, P. MHC class I and II expression in prostate carcinoma and modulation by interferon-α and -γ. Prostate, 33: 233-239, 1997.
66. Kim, J. J., Trivedi, N. N., Wilson, D. M., Mahalingam, S., Morrison, L., Tsai, A., Chattergoon, M. A., Dang, K., Patel, M., Ahn, L., Boyer, J. D., Chalian, A. A., Schoemaker, H., Kieber-Emmons, T., Agadjanyan, M. A., and Weiner, D. B. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine, Oncogene. 17: 3125-3135, 1998.
67. Slovin, S. F., Ragupathi, G., Adluri, S., Ungers, G., Terry, K., Kim, S., Spassova, M., Bornmann, W. G., Fazzari, M., Dantis, L., Olkiewicz, K., Lloyd, K. O., Livingston, P. O., Danishefsky, S. J., and Scher, H. I. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl. Acad. Sci. USA, 96: 5710-5715, 1999.
68. Sanda, M. G., Smith, D. C., Charles, L. G., Hwang, C., Pienta, K. J., Schlom, J., Milenic, D., Panicali, D., and Montie, J. E. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology, 53: 260-266, 1999.
69. Murphy, G. P., Tjoa, B. A., Simmons, S. J., Jarisch, J., Bowes, V. A., Ragde, M., Elgamal, A., Kenny, G. M., Cobb, O. E., Ireton, R. C., Troychak, M. J., Salgaller, M. L., and Boynton, A. L. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a Phase II prostate cancer vaccine trials involving patients with hormone-refractory metastatic disease. Prostate, 38: 73-78, 1999.
70. Gilboa, E., Nair, S. K., and Lyerly, H. K. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother., 46: 82-87, 1998.